Eli Lilly Acquires Engage Biologics in $202M Deal
Eli Lilly has acquired pre-clinical biotech company Engage Biologics for up to $202 million in cash. The deal, announced on Wednesday, aims to advance non-viral DNA delivery systems.
Tickers: $LLY
More World news
- Al Mouj Muscat Receives Three Architectural Awards at International and Arabian Property Awards 2026
- SoftBank Reports $7.1 Billion Quarterly Loss Driven by Natural Gas Turbine Over-Ordering
- PayPal and Kiva Renew Long-Term Partnership to Support Global Microloans
- Tesla to Discontinue Cybertruck Production by Summer 2027 to Prioritize Cybercab
- Absci Reports Q3 2026 Financial Results and Clinical Updates for ABS-201
- Acurx Pharmaceuticals Reports Q3 2026 Financial Results and Initiates PATHFINDER Trial Enrollment
- Fermi Inc. Reports Q3 2026 Net Loss of $141.6 Million Amid Infrastructure Expansion
- Google Wallet Introduces Digital Home Key Support via Aliro Standard
- Analyst Ming-Chi Kuo Suggests Nvidia CEO Resignation May Have Limited Near-Term Stock Impact
- Solo Brands Lowers Net Sales Outlook While Projecting 2026 Adjusted EBITDA Growth